Sahajanand Medical Technologies Limited (SMT) announced its financial results for the second quarter and first half of fiscal year 2026-27. The company reported a 25% year-on-year revenue growth for H1 FY27, reaching ₹7,251 million. EBITDA also saw a substantial increase of 43% to ₹1,141 million, with an improved EBITDA margin of 15.7%. Q2 FY27 was highlighted as the company’s best quarter yet, achieving record revenue, EBITDA, and PAT.
SMT Announces Strong Financial Performance for Q2 and H1 FY27
Sahajanand Medical Technologies Limited (SMT) has released its financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2026-27, ending September 30, 2026. The company declared a robust performance, marked by significant year-on-year growth in key financial metrics.
H1 FY27 Highlights
For the first half of FY27, SMT recorded a total revenue of ₹7,251 million, representing a 25% increase compared to the same period in the previous year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by an impressive 43% to ₹1,141 million. This growth was accompanied by an expansion in the EBITDA margin, which improved by approximately 200 basis points to reach 15.7% in H1 FY27, up from 13.7% in H1 FY26.
Record Quarter in Q2 FY27
The second quarter of FY27 emerged as SMT’s best-performing quarter to date. During Q2 FY27, the company achieved its highest-ever quarterly revenue, EBITDA, and Profit After Tax (PAT). Revenue for the quarter stood at ₹3,734 million, up 24.7% year-on-year. EBITDA for Q2 FY27 was ₹656 million, a 36.6% increase YoY, with a corresponding margin of 17.6%. PAT for the quarter reached ₹265 million, marking a 26.6% YoY growth.
Product Portfolio and Operational Efficiency
The company also reported strengthening of its product portfolio, with the commercialization of its sirolimus drug-coated balloon, Sironity, in India. Progress was also noted in the TAVI platform, including Hydra Elevate and a redesigned AVDC 1.5 delivery system. SMT emphasized its continued focus on operational efficiency to improve margins through a richer product mix, vertical integration, better plant utilization, and overhead control. Priorities remain disciplined execution, sustained R&D investment, clinical evidence generation, and improved cash flow quality.
Key Financial Metrics
In H1 FY27, ROCE (Return on Capital Employed) was reported at 16.7% and ROE (Return on Equity) at 11.2%, indicating improved returns on capital and shareholder equity. The cash conversion cycle has been reduced to 128 days in H1 FY27 from 138 days in FY26, demonstrating enhanced working capital management. Cash from operations also saw a significant increase, up 2.6x since FY24.
Source: BSE
